Onderneming UCB SA OTC Markets

UCBJY

US9034801012

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per regio

Ratings voor UCB SA

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Biofarmaceutica

Beurs gesloten - OTC Markets Andere beurzen 21:50:39 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
69,68 ^USD	+1,84%		+0,17%	+59,82%

31/05	UCB krijgt positief advies van CHMP	AM
23/05	UCB publiceert fase 3-studies met bimekizumab in The Lancet	AM

UCB is een internationaal biofarmaceutisch bedrijf dat zich toelegt op het ontdekken en ontwikkelen van innovatieve geneesmiddelen en oplossingen voor het transformeren van het leven van mensen met ernstige ziekten van het immuunsysteem of het centraal zenuwstelsel.

Aantal werknemers: 8 767

EUR in miljoen	2022	Gewicht	2023	Gewicht	Delta
Biopharmaceuticals 100,0 %	5 140	100,0 %	4 867	100,0 %	-5,31%

EUR in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 50,4 %	2 902	56,5 %	2 454	50,4 %	-15,44%
Other Countries 11,4 %	507	9,9 %	554	11,4 %	+9,27%
Europe - Other 7,5 %	348	6,8 %	365	7,5 %	+4,89%
Germany 6,4 %	330	6,4 %	310	6,4 %	-6,06%
Japan 5,5 %	324	6,3 %	269	5,5 %	-16,98%
Spain 4,6 %	213	4,1 %	224	4,6 %	+5,16%
France (including French Territories) 3,3 %	169	3,3 %	162	3,3 %	-4,14%
China 3,1 %	159	3,1 %	151	3,1 %	-5,03%
Italy 2,9 %	154	3,0 %	143	2,9 %	-7,14%
United Kingdom and Ireland 2,7 %	151	2,9 %	133	2,7 %	-11,92%
Belgium 1,1 %	49	1,0 %	52	1,1 %	+6,12%
Global 1,0 %	-167	-3,2 %	50	1,0 %	-129,94%

Managers	Titel	Leeftijd	Van
Jean-Christophe Tellier CEO	Chief Executive Officer	65	01-06-11
Sandrine Dufour DFI	Director of Finance/CFO	57	01-07-20
Dhavalkumar Patel CTO	Chief Tech/Sci/R&D Officer	63	01-10-17
Kirsten Lund Jurgensen CTO	Chief Tech/Sci/R&D Officer	65	01-01-19
Iris Löw-Friedrich CTO	Chief Tech/Sci/R&D Officer	63	01-09-06
Antje Witte IRC	Investor Relations Contact	-	-
Dominique Baeten PRN	Corporate Officer/Principal	-	-
Thomas Debeys AUD	Comptroller/Controller/Auditor	-	-
Jean Fleurial HRO	Human Resources Officer	59	01-09-17
Emmanuel Caeymaex PRN	Corporate Officer/Principal	-	01-03-94

Besturend	Titel	Leeftijd	Van
Ulf Arne Wiinberg BRD	Director/Board Member	66	28-04-16
Dame Davies BRD	Director/Board Member	73	01-01-14
Jean-Christophe Tellier CEO	Chief Executive Officer	65	01-06-11
Cyril Janssen BRD	Director/Board Member	53	01-01-15
Jan Berger BRD	Director/Board Member	67	01-04-19
Jonathan Peacock CHM	Chairman	66	01-01-21
Maëlys Castella BRD	Director/Board Member	58	01-01-23
Jonkheer Cédric van Rijckevorsel BRD	Director/Board Member	54	24-04-14
Charles-Antoine Janssen BRD	Director/Board Member	53	01-01-01
Pierre Gurdjian BRD	Director/Board Member	63	28-04-16

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	1	194 505 658	119 501 352 ( 61,44 %)	4 755 075 ( 2,445 %)	61,44 %

Naam	Aandelen	%	Totale waarde
FINANCIÈRE DE TUBIZE S.A. 36,04 %	70 090 611	36,04 %	9 334 M $
Wellington Management Co. LLP 6,555 %	12 749 947	6,555 %	1 698 M $
UCB 2,445 %	4 755 075	2,445 %	633 M $
BNP Paribas Asset Management Belgium SA 0,8537 %	1 660 558	0,8537 %	221 M $
FMR Investment Management (UK) Ltd. 0,4947 %	962 306	0,4947 %	128 M $
State Street Global Advisors Ltd. 0,4298 %	835 916	0,4298 %	111 M $
Wellington Management International Ltd. 0,4210 %	818 860	0,4210 %	109 M $
Amundi Asset Management SA (Investment Management) 0,3494 %	679 593	0,3494 %	91 M $
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0,2552 %	496 323	0,2552 %	66 M $
Mackenzie Investments Europe Ltd. 0,2496 %	485 503	0,2496 %	65 M $

Naam	Aandelen	%	Totale waarde
RhumbLine Advisers LP 0,000990 %	3 852	0,000990 %	258 123 $
GAMMA Investing LLC 0,000032 %	125	0,000032 %	8 376 $
PNC Investments LLC 0,000001 %	5	0,000001 %	335 $

Naam	Aandelen	%	Totale waarde
UCB 2.44%	4 755 075	2.44%	633 257 541 $
HEIDELBERG PHARMA AG 2.43%	1 131 186	2.43%	3 640 654 $

UCB SA

Allée de la Recherche, 60

1070, Brussels

+32 2 559 99 99

http://www.ucb.com

Naam	Categorie en sector
UCB Manufacturing Ireland Ltd.
UCB Fipar SA UCB Fipar SA Financial ConglomeratesFinance Part of UCB SA, UCB Fipar SA is an investment holding Belgian company. The company is based in Anderlecht, Belgium. UCB Fipar was founded in 1947.	Financial Conglomerates
UCB Ventures Belgium SA	Investment Managers
UCB Pharma GmbH UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany.	Pharmaceuticals: Major
UCB Pharma SA (Belgium) UCB Pharma SA (Belgium) Pharmaceuticals: MajorHealth Technology UCB Pharma SA discovers and develops biopharmaceutical products. It is a biopharmaceutical company focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is headquartered in Brussels, Belgium.	Pharmaceuticals: Major
UCB Ventures SA	Investment Managers
Ucb Belgium SA Ucb Belgium SA Pharmaceuticals: MajorHealth Technology Part of UCB SA, UCB Belgium SA is a Belgian bio-pharmaceutical company that focuses on neurology and immunology. The company is based in Brussels, Belgium. The company was founded by Emmanuel Janssen.	Pharmaceuticals: Major
UCB Pharma Ltd. UCB Pharma Ltd. Pharmaceuticals: MajorHealth Technology UCB Pharma Ltd. operates as a biopharmaceutical company. The firm focuses on developing medicines for severe diseases in Immunology and CNS. The company is headquartered in Slough, the United Kingdom.	Pharmaceuticals: Major
UCB Biopharma SRL UCB Biopharma SRL Medical DistributorsDistribution Services Part of UCB SA, UCB Biopharma SRL is a Belgian pharmaceutical company founded in 2013. The company is based in Brussels, Belgium. UCB Biopharma specializes in the development of treatments for various medical conditions, including axial spondyloarthritis, psoriatic arthritis, and other health issues. The company also manages the UCB Community Health Fund and holds an annual shareholders meeting.	Medical Distributors
Zogenix International Ltd. Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom.	Pharmaceuticals: Major

Trading rating

Beleggingsrating

ESG Refinitiv

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Accumuleren

Aantal analisten

Laatste slotkoers

128,6 EUR

Gemiddelde koersdoel

126,4 EUR

Spread / Gemiddelde doel

-1,76%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Biofarmaceutica

	Vaira. 1 jan.	Kapi.
CSL LIMITED	-2,29%	89,87 mld.
SAMSUNG BIOLOGICS CO.,LTD.	-3,95%	37,57 mld.
BIOMARIN PHARMACEUTICAL INC.	-22,14%	14,25 mld.
INCYTE CORPORATION	-7,96%	12,99 mld.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,33%	11,93 mld.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46,33%	10,84 mld.
SWEDISH ORPHAN BIOVITRUM AB	+5,77%	9,11 mld.
INNOVENT BIOLOGICS, INC.	-17,66%	7,32 mld.
ALTEOGEN INC.	+88,73%	7,14 mld.

Biofarmaceutica